Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid TumorsTimothy A Yap, Brent O'Carrigan, Marina S Penney, et al.Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.Cancer Research|April 23, 2021
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in CancerRoman M Chabanon, Daphné Morel, Thomas Eychenne, et al.Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.Nature|August 13, 2025
NASP modulates histone turnover to drive PARP inhibitor resistanceSarah C Moser, Anna Khalizieva, Josef Roehsner, et al.Pageof 6